Rectal Cancer

P=N/A, N=30, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

P=N/A, N=150, Active, not recruiting, Insel Gruppe AG, University Hospital Bern | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P=N/A, N=20, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital

P=N/A, N=276, Recruiting, Peking University First Hospital; Peking University First Hospital

P=N/A, N=291, Not yet recruiting, Shaanxi Provincial People's Hospital; Shaanxi Provincial People's Hospital

P=N/A, N=60, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University

P=N/A, N=218, Not yet recruiting, Shaanxi Provincial People's Hospital; Shaanxi Provincial People's Hospital

P=N/A, N=40, Not yet recruiting, The First Affiliated Hospital Of Zhengzhou University; The First Affiliated Hospital Of Zhengzhou University

P=N/A, N=8000, Not yet recruiting, First Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Kunming Medical University

P=N/A, N=296, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P=N/A, N=100, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P=N/A, N=0, Not yet recruiting, Beijing Cancer Hospital; Beijing Hospitals Authority

P=N/A, N=10, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital

P2, N=33, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P1, N=30, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P=N/A, N=63, Completed, Institut Cancerologie de l'Ouest | Recruiting --> Completed

P=N/A, N=200, Recruiting, Washington University School of Medicine | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=23, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting

P1/2, N=85, Recruiting, Essen Biotech | Not yet recruiting --> Recruiting

P=N/A, N=1275, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

P=N/A, N=200, Recruiting, Imperial College London | Not yet recruiting --> Recruiting | N=146 --> 200 | Trial completion date: Apr 2032 --> Dec 2031 | Trial primary completion date: Apr 2032 --> Dec 2026

The 5-year relapse-free survival rate was 88.5% in the LS group and 90.5% in the RS group (P = 0.525); the respective 5-year overall survival rates were 97.3 and 93.8% (P = 0.283). The 5-year cumulative local and distant recurrence rates were 3.3% vs. 3.3% (P = 0.665) and 9.7% vs. 7.7% (P = 0.464) in the LS and RS groups, respectively Robotic surgery can be a feasible treatment modality for rectal cancer, with lower frequencies of postoperative ileus and Clavien-Dindo grade II or higher complications than laparoscopic surgery and no difference in long-term outcomes.

No abstract available

P=N/A, N=100, Recruiting, Gazi University

Mangiferin has confirmed potential benefits in lung, cervical, breast, brain, and prostate cancers as well as leukemia whether administered alone or in combination with recognized anticancer compounds. More clinical trials and research investigations are required to completely unleash the potential of mangiferin, which may lower the risk of cancer onset and act as a preventive and therapeutic alternative for a number of cancers.

The results also showed that different TWIST1 methylation loci may deregulate TWIST1 expression in different cancer types. The inference that can be drawn from this study is that TWIST1 DNA methylation is an important TWIST1 deregulation mechanism in colon, rectal and gastric cancers.

P=N/A, N=120, Active, not recruiting, Grupo Espanol Multidisciplinario del Cancer Digestivo | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Apr 2025

Consequently, we determined that the patient presented with a condition similar to immune thrombocytopenic purpura (ITP) and selected a treatment approach consisting of eltrombopag, a thrombopoietin receptor agonist. Although uncommon, anti-HER2 antibodies can cause severe thrombocytopenia. Furthermore, if thrombocytopenia persists after treatment discontinuation and the administration of corticosteroids, exploring treatment options aligned with managing ITP is essential.

P2, N=110, Not yet recruiting, Fudan University

P=N/A, N=110, Active, not recruiting, Zhongnan Hospital

P2, N=77, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024

P=N/A, N=40, Recruiting, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting --> Recruiting

P2, N=312, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Sep 2024 --> Sep 2025

Although significant improvements in CRC management have occurred globally in recent years, a strategic approach leading to population-based systemic solutions is required. The high incidence of young-onset CRC and the growing elderly population due to a rise in life expectancy will be especially important factors for countries with limited healthcare resources like Serbia.

In this single-center, prospective, randomized controlled trial, we randomly assigned (1 : 1) patients with locally advanced rectal cancer with wild-type RAS/BRAF gene to two groups: 5 cycles of modified leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin combination regimen (modified FOLFOX6, mFOLFOX6) concurrent with 25 times radiotherapy or 5 cycles of mFOLFOX6 plus cetuximab, all with subsequent total mesorectal excision (TME) resection and adjuvant chemotherapy. Additionally, lower rates of preventive enterostomy and low anterior resection syndrome were shown in the mFOLFOX6-Cet group compared to the mFOLFOX6-RT group. The neoadjuvant treatment strategy of mFOLFOX6 with cetuximab is feasible and promising for patients with locally advanced rectal cancer, even superior to mFOLFOX6 with radiotherapy.

P2, N=322, Completed, Asan Medical Center | Unknown status --> Completed

P=N/A, N=57, Active, not recruiting, Sengkang General Hospital | Trial completion date: Jun 2024 --> Dec 2024

Microvascular density appears highest in cases of complete tumour response to neoadjuvant therapy, similar to normal rectal tissue. The histological microvascular patterns seen in treated tissue may explain the imaging patterns seen in photoacoustic microscopy.

P2, N=124, Not yet recruiting, Fudan University

The APTw value had moderate diagnostic performance in the prediction of KRAS mutation with a high sensitivity but a low specificity. APTw MRI might be a promising supplement to KRAS genomic analysis in rectal cancer patients.

In this study, mISb demonstrates significant prognostic value in LARC patients receiving preoperative therapies, especially in the TNT subgroup. These findings may help tailor the intensity of neoadjuvant therapy for patients.

P=N/A, N=1000, Active, not recruiting, Tempus AI | Recruiting --> Active, not recruiting